It often gets maligned by drug makers and others, he said
This contrasts with exenatide and lixisenatide, which showed clearer motor effects, possibly due to differences in drug properties, trial design, or patient characteristics [54, 56]
They added that while many of the studies are limited by small sample sizes, short follow-up and a lack of control groups, further study of these medications in PsA and RA are warranted
(And while slightly increasing GLP-1 levels wont result in extreme weight loss, you certainly dont want to cause them to nosedive, either.) A 2023 study found that folks with a misaligned circadian rhythm (due to factors like night shift work or insomnia) tend to have a low GLP-1 response and a high risk of insulin resistance and obesity (18)
GLP-1 medications typically require gradual dose escalation over several weeks to months to reach therapeutic levels whilst minimising gastrointestinal side effects